Please ensure Javascript is enabled for purposes of website accessibility

3 Top Healthcare Stocks to Buy in January

By Keith Speights - Jan 4, 2020 at 12:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Three very different areas of healthcare. One big common denominator: great growth prospects.

A new year is here. And so are new opportunities to profit from healthcare stocks

Three healthcare stocks that look like smart picks to buy in January are Axsome Therapeutics (AXSM 9.66%), Guardant Health (GH 11.63%), and Intuitive Surgical (ISRG 2.62%). Here's why these stocks could be poised to deliver tremendous gains.

Healthcare professional holding a tablet with healthcare-related images appearing over the tablet.

Image source: Getty Images.

1. Axsome Therapeutics

Axsome ranked as the top-performing biotech stock of 2019 with its shares skyrocketing close to 3,600%. The fireworks started early in the year with encouraging results for experimental drug AXS-05 in a phase 2 clinical study targeting treatment of major depressive disorder. Axsome reported great results late in 2019 for AXS-05 in a pivotal late-stage study.

But is Axsome still a stock to buy after its massive gains? I think so. There should still be plenty of room to run if AXS-05 wins Food and Drug Administration approval. There's no guarantee that will happen, but my view is that the odds look pretty good based on the late-stage results.

AXS-05 holds the potential to achieve peak annual sales of around $1.5 billion for treating depression. Axsome is also evaluating the drug in a late-stage study targeting Alzheimer's disease agitation. That indication could tack on another $1 billion or so in potential peak annual sales. With its market cap currently at $1.8 billion, I think this stock is still a winner.

2. Guardant Health

Guardant Health delivered a 107% return last year, which might not seem nearly as impressive following a discussion of Axsome's performance but is still enough to land a spot among the top healthcare stocks of 2019. The company's success stemmed from rapidly growing sales of Guardant360 and GuardantOmni, liquid biopsies that detect cancer by finding tiny fragments of DNA broken off from tumor cells.

Even after tremendous sales growth in 2019, Guardant Health is still only its early innings. The company's addressable market for Guardant360 and GuardantOmni is around $6 billion. But its LUNAR liquid biopsies, which currently are only available for research use, could open the door to an addressable market topping $45 billion annually.

Guardant Health isn't likely to capture all of that addressable market. There are other companies developing liquid biopsies. However, Guardant Health is already the leader in the market and should be well on its way to grabbing a significant market share.

3. Intuitive Surgical

Intuitive Surgical might really look like an underachiever in comparison to Axsome and Guardant Health with its 2019 gain of 23%. However, the robotic surgical systems pioneer claims an important feather in its cap that the smaller companies don't: It's highly profitable.

My colleague Sean Williams wrote last month that the stock "comes awfully close to being a surefire investment." I think that he's right. Intuitive's recurring revenue makes up more than 70% of its total revenue. Its track record and head start in robotic surgery give it a significant competitive advantage.

The company's growth opportunities remain very strong as well. Aging demographics trends in the U.S. and across the world should drive demand for the types of surgical procedures for which Intuitive's da Vinci system is ideally suited. Intuitive also continues to introduce innovative new products that expand the types of procedures for which robotic surgical assistance adds value. 


I'd be remiss if I didn't point out the risks that these three stocks face. The obvious risk for Axsome Therapeutics is that it could fail to secure FDA approval for AXS-05. Even if the drug is approved, Axsome's commercial launch potentially could go worse than expected.

As mentioned earlier, Guardant Health faces competition. The company also hopes to secure FDA clearance for Guarant360. Failure to do so would hurt the stock.

Intuitive Surgical is the least risky of these three stocks, but it isn't risk-free. New rivals, notably including giant medical device maker Medtronic, plan to challenge the company's dominance in the robotic surgical systems market.

Despite these risks, though, I think that Axsome, Guardant Health, and Intuitive Surgical are great healthcare stocks to buy in January and hold for many Januaries to come.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
$229.16 (2.62%) $5.86
Guardant Health, Inc. Stock Quote
Guardant Health, Inc.
$43.00 (11.63%) $4.48
Axsome Therapeutics, Inc. Stock Quote
Axsome Therapeutics, Inc.
$26.46 (9.66%) $2.33
Medtronic plc Stock Quote
Medtronic plc
$99.08 (-0.36%) $0.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.